Virulizin Granted Orphan-Drug Status in the European Union
Lorus Therapeutics has announced that the European Medicines Agency has given a positive opinion on Lorus' application for orphan-drug status to Virulizin, the company's lead anticancer drug for the treatment of pancreatic cancer.
This most recent orphan-drug status designation for Virulizin indicates that the product has potential to provide efficacy and a significant benefit to patients with this devastating condition.
This positive opinion also strengthens the product's position in the European Union (EU), as the Phase III global registration clinical trial in pancreatic cancer nears completion during the second half of this calendar year. Virulizin received orphan-drug status for pancreatic cancer in the U.S. from the FDA in 2001.